The very first human trials of a treatment using induced pluripotent stem cells (iPS cells) in Japan will begin as early as next year, the government-backed Riken research institute announced on June 12.
Speaking at a meeting of the Japanese Society for Regenerative Medicine in Yokohama, research team leader Masayo Takahashi of the Riken Center for Developmental Biology detailed plans to begin using iPS treatments on patients with a degenerative eye condition. Transplanted iPS cells have not developed into cancer in animal testing, and the clinical trial will go ahead now that it’s confirmed that similar procedures do not pose
Image via Wikipedia
Madison, Wisconsin – Soon, some treatments for blinding eye diseases might be developed and tested using retina-like tissues produced from the patient’s own skin, thanks to a series of discoveries reported by a team of University of Wisconsin-Madison stem cell researchers.
The team, led by stem cell scientist and ophthalmologist Dr. David Gamm of the UW School of Medicine and Public Health and former UW scientist Dr. Jason Meyer, used human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells to generate three-dimensional structures that are similar to those present at the earliest stages of retinal
Deep in the brain, buried in the hippocampus and subventricular zone, reside adult neural stem cells, cells that retain the ability to become other types of neural cells and could serve as possible treatments for ailments ranging from vision impairment to Parkinson’s to spinal cord injuries. Doctors, scientists and patients, however, are understandably hesitant to go digging around for them, their location being “a great deterrent,” Sally Temple, founder of the New York Neural Stem Cell Institute, said at the 2009 World Stem Cell Summit here on Wednesday.
Researchers, therefore, are anxious to uncover other, more accessible neural stem cell
Advanced Cell Technology, a leader in the field of regenerative medicine, today announced treatment of the first patient in its Phase 1/2 clinical trial for Stargardt’s macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The surgery was performed on Friday, Jan. 20, at the Moorfields Eye Hospital in London by a team of surgeons led by Professor James Bainbridge, consultant surgeon at Moorfields and Chair of Retinal Studies at University College London. The patient successfully underwent the procedure without any complications. ACT and Moorfields Eye Hospital received clearance in September from
University at Buffalo researchers will test the effectiveness of using stem cells from donors to treat patients with heart failure.
The National Heart, Lung and Blood Institute has awarded $2 million for the four-year translational animal study.
The results could pave the way for a similar trial in humans and eventually help make stem cell therapy more widely available (…)